Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2026, AngioDynamics, Inc. reported revenue of $320M, up 9.5% year over year. Operating margin was -12.5% and net margin -11.5%, on a free-cash-flow margin of 0.2% with capital expenditure at 0.8% of revenue. Every figure is computed directly from ANGO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $320M | -12.5% | -11.5% |
| FY2025 | $292M | -13.7% | -11.6% |
| FY2024 | $304M | -63.3% | -60.7% |
| FY2023 | $339M | -15.1% | -15.5% |
| FY2022 | $316M | -9.0% | -8.4% |
How does ANGO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: A · ACHR · AEHR · AERG · AEVA · AIRI
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.